04:01 AM EDT, 04/28/2025 (MT Newswires) -- (Updates to add more information in the third, fourth, and sixth paragraphs.)

SpringWorks Therapeutics ( SWTX ) has agreed to be acquired by German technology firm Merck KGaA for $47 per share in cash, the companies said in a joint statement Monday.

The consideration represents about $3.9 billion in equity value, or $3.4 billion in enterprise value, for SpringWorks.

Merck plans to fund the deal using its available cash and new debt.

The addition of SpringWorks is expected to boost Merck's healthcare business in the US, which operates as EMD Serono.

The deal is expected to close in H2, subject to regulatory approvals and customary closing conditions.

Merck expects the business combination to immediately contribute to its revenue upon closing and be accretive to its earnings per share in 2027.